Responsiveness to a physiological regimen of GnRH therapy and relation to genotype in women with isolated hypogonadotropic hypogonadism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages

  Abel, Brent S ^a   Shaw, Natalie D ^a,b   Brown, Jenifer M ^a   Adams, Judith M ^a   Alati, Teresa ^a   Martin, Kathryn A ^a   Pitteloud, Nelly ^c   Seminara, Stephanie B ^a   Plummer, Lacey ^a   Pignatelli, Duarte ^d   William F Crowley, ^a   Welt, Corrine K ^a   Hall, Janet E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOLLITROPIN; GONADORELIN; GONADORELIN RECEPTOR; GONADOTROPIN; LUTEINIZING HORMONE; SEX HORMONE;

ADOLESCENT; ADULT; ARTICLE; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 7 GENE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE; FOLLITROPIN RELEASE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GNRHR GENE; GONADOTROPIN BLOOD LEVEL; HORMONE RESISTANCE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; ISOLATED HYPOGONADOTROPIC HYPOGONADISM; KAL1 GENE; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROKINETICIN RECEPTOR 2 GENE; RETROSPECTIVE STUDY; TACHYKININ 3 GENE; TACHYKININ RECEPTOR 3 GENE; TREATMENT RESPONSE;

EID: 84873637815     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3294     Document Type: Article

References (63)

1. Balasubramanian R, Crowley WF Jr. Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network. Mol Cell Endocrinol. 2011; 346(1-2):4 -12.
2. Martin K, Santoro N, Hall J, Filicori M, Wierman M, Crowley WF Jr. Clinical review 15: management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab. 1990;71(5):1081A-1081G.
3. Sykiotis GP, Hoang XH, Avbelj M, et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab. 2010;95(6): 3019-3027.
4. Seminara SB, Beranova M, Oliveira LM, Martin KA, Crowley WF Jr, Hall JE. Successful use of pulsatile gonadotropin-releasing hormone (GnRH) for ovulation induction and pregnancy in a patient with GnRH receptor mutations. J Clin Endocrinol Metab. 2000; 85(2):556-562.
5. Brinkmeier ML, Davis SW, Carninci P, et al. Discovery of transcriptional regulators and signaling pathways in the developing pituitary gland by bioinformatic and genomic approaches. Genomics. 2009; 93(5):449-460.
6. Ericson J, Norlin S, Jessell TM, Edlund T. Integrated FGF and BMP signaling controls the progression of progenitor cell differentiation and the emergence of pattern in the embryonic anterior pituitary. Development. 1998;125(6):1005-1015.
7. Ikeda Y, Swain A, Weber TJ, et al. Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development. Mol Endocrinol. 1996;10(10):1261-1272.
8. Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H, Zhou QY. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem. 2002; 277(22):19276-19280.
9. McCabe MJ, Gaston-Massuet C, Tziaferi V, et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J Clin Endocrinol Metab. 2011;96(10):E1709- E1718.
10. Sanlaville D, Etchevers HC, Gonzales M, et al. Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development. J Med Genet. 2006;43(3):211-217.
11. Asakai R, Song SY, Itoh N, Yamakuni T, Tamura K, Okamoto R. Differential gene expression of fibroblast growth factor receptor isoforms in rat ovary. Mol Cell Endocrinol. 1994;104(1):75-80.
12. Cejudo RA, Pinto FM, Dorta I, et al. Analysis of the expression of neurokinin B, kisspeptin, and their cognate receptors NK3R and KISS1R in the human female genital tract. Fertil Steril. 2012;97(5): 1213-1219.
13. Choi JH, Gilks CB, Auersperg N, Leung PC. Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab. 2006;91(11):4562-4570.
14. Ferrara N, Frantz G, LeCouter J, et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derivedVEGFin normal and polycystic human ovaries. Am J Pathol. 2003;162(6):1881-1893.
15. Gaytan F, Gaytan M, Castellano JM, et al. KiSS-1 in the mammalian ovary: distribution of kisspeptin in human and marmoset and alterations in KiSS-1 mRNA levels in a rat model of ovulatory dysfunction. Am J Physiol Endocrinol Metab. 2009;296(3):E520-E531.
16. Ghosh P, Saha SK, Bhattacharya S, Bhattacharya S, Mukherjee S, Roy SS. Tachykinin family genes and their receptors are differentially expressed in the hypothyroid ovary and pituitary. Cell Physiol Biochem. 2007;20(5):357-368.
17. Hu Y, Yu H, Shaw G, Pask AJ, Renfree MB. Kallmann syndrome 1 gene is expressed in the marsupial gonad. Biol Reprod. 2011;84(3): 595-603.
18. Sato Y, Suzuki T, Hidaka K, et al. Immunolocalization of nuclear transcription factors, DAX-1 and COUP-TFII, in the normalhuman ovary: correlation with adrenal 4 binding protein/steroidogenic factor-1 immunolocalization during the menstrual cycle. J Clin Endocrinol Metab. 2003;88(7):3415-3420.
19. Valve E, Penttila TL, Paranko J, Harkonen P. FGF-8 is expressed during specific phases of rodent oocyte and spermatogonium development. Biochem Biophys Res Commun. 1997;232(1):173-177.
20. Shaw ND, Seminara SB, Welt CK, et al. Expanding the phenotype and genotype of female GnRH deficiency. J Clin Endocrinol Metab. 2011;96(3):E566-E576.
21. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94(2 Pt 1):176-178.
22. Hayes FJ, McNicholl DJ, Schoenfeld D, Marsh EE, Hall JE. Free α-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. J Clin Endocrinol Metab. 1999;84(3):1028-1036.
23. Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest. 1973;52(10):2617-2628.
24. Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature. 2002;417(6887):405-410.
25. Cole LW, Sidis Y, Zhang C, et al. Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab. 2008;93(9):3551-3559.
26. de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med. 1997;337(22):1597-1602.
27. Falardeau J, Chung WC, Beenken A, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest. 2008;118(8):2822-2831.
28. Gianetti E, Tusset C, Noel SD, et al.TAC3/TACR3mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab. 2010;95(6):2857-2867.
29. Lalani SR, Safiullah AM, Fernbach SD, et al. Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. Am J Hum Genet. 2006;78(2):303-314.
30. Miura K, Acierno JS Jr, Seminara SB. Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). J Hum Genet. 2004;49(5):265-268.
31. Oliveira LM, Seminara SB, Beranova M, et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab. 2001;86(4):1532-1538.
32. Pitteloud N, Zhang C, Pignatelli D, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA. 2007;104(44):17447-17452.
33. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627.
34. Beranova M, Oliveira LM, Bedecarrats GY, et al. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2001;86(4):1580-1588.
35. Costa EM, Bedecarrats GY, Mendonca BB, Arnhold IJ, Kaiser UB, Latronico AC. Two novel mutations in the gonadotropin-releasing hormone receptor gene in Brazilian patients with hypogonadotropic hypogonadism and normal olfaction. J Clin Endocrinol Metab. 2001;86(6):2680-2686.
36. Meysing AU, Kanasaki H, Bedecarrats GY, et al. GNRHR mutations in a woman with idiopathic hypogonadotropic hypogonadism highlight the differential sensitivity of luteinizing hormone and follicle-stimulating hormone to gonadotropin-releasing hormone. J Clin Endocrinol Metab. 2004;89(7):3189-3198.
37. Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest. 2007;117(2):457-463.
38. Sunyaev S, Ramensky V, Koch I, Lathe WIII, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet. 2001; 10(6):591-597.
39. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. Mutation-Taster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575-576.
40. Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 2003;31(1):334-341.
41. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812-3814.
42. Ferrer-Costa C, Gelpi JL, Zamakola L, et al. a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics. 2005;21(14):3176-3178.
43. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37(9):e67.
44. Taylor AE, Whitney H, Hall JE, Martin K, Crowley WFJr. Midcycle levels of sex steroids are sufficient to recreate the follicle-stimulating hormone but not the luteinizing hormone midcycle surge: evidence for the contribution of other ovarian factors to the surge in normal women. J Clin Endocrinol Metab. 1995;80(5):1541-1547.
45. Welt CK, Adams JM, Sluss PM, Hall JE. Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development. J Clin Endocrinol Metab. 1999;84(6):2163-2169.
46. Welt CK, Falorni A, Taylor AE, Martin KA, Hall JE. Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels. J Clin Endocrinol Metab. 2005;90(5):3069-3076.
47. Filicori M, Santoro N, Merriam GR, Crowley WF Jr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab. 1986;62(6):1136-1144.
48. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(7):2248-2256.
49. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab. 1997;82(11):3728-3733.
50. Pagan YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab. 2006;91(4):1309-1316.
51. Chikazawa K, Araki S, Tamada T. Morphological and endocrinological studies on follicular development during the human menstrual cycle. J Clin Endocrinol Metab. 1986;62(2):305-313.
52. Gross KM, Matsumoto AM, Bremner WJ. Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man. J Clin Endocrinol Metab. 1987;64(4):675-680.
53. Raivio T, Sidis Y, Plummer L, et al. Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2009; 94(11):4380-4390.
54. Hoffman AR, Crowley WF Jr. Induction of puberty in men by longterm pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307(20):1237-1241.
55. Hadziselimovic F, Thommen L, Girard J, Herzog B. The significance of postnatal gonadotropin surge for testicular development in normal and cryptorchid testes. J Urol. 1986;136(1 Pt 2):274-276.
56. Gianetti E, Hall JE, Au MG, et al. When genetic load does not correlate with phenotypic spectrum: lessons from the GnRH receptor (GNRHR). J Clin Endocrinol Metab. 2012;97(9):E1798-E1807.
57. Raivio T, Avbelj M, McCabe MJ, et al. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J Clin Endocrinol Metab. 2012;97(4):E694-E699.
58. Reynaud R, Jayakody SA, Monnier C, et al. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. J Clin Endocrinol Metab. 2012;97(6):E1068-E1073.
59. Kim HG, Kurth I, Lan F, et al. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet. 2008; 83(4):511-519.
60. Layman WS, Hurd EA, Martin DM. Reproductive dysfunction and decreased GnRH neurogenesis in a mouse model of CHARGE syndrome. Hum Mol Genet. 2011;20(16):3138-3150.
61. St-Amand J, Yoshioka M, Tanaka K, Nishida Y. Transcriptomewide identification of preferentially expressed genes in the hypothalamus and pituitary gland. Front Endocrinol (Lausanne). 2011; 2:111.
62. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999;84(10):3686-3695.
63. Clement K, Vaisse C, Lahlou N, et al. Amutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392(6674):398-401.